# A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

> **NCT04034290** · PHASE2 · COMPLETED · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 224 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** GamFluVac
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04034290
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-07-31
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2020-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034290, "A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04034290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*